Market depressed on Cyberonics new market ploy
This article was originally published in Clinica
Executive Summary
Shares in Cyberonics, a US device company aimed at managing epilepsy and other neurological disorders through pulsed electrical stimulation of the vagus nerve, fell to a 52-week low following the announcement of its third quarter results and a plan to tap into the market for depression therapy. Industry analysts called the plan "over-aggressive", addressing a market that will not be large enough to compensate the company for the size of investment it is making.